Tango Therapeutics, Inc.
TNGX
$27.07
-6.66%
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing precision oncology therapies, with a pipeline centered on MTA-cooperative PRMT5 inhibitors for cancers such as pancreatic, lung, and glioblastoma. As a clinical-stage biotech, it operates in a highly competitive landscape, differentiating itself through a synthetic lethality approach targeting specific genetic vulnerabilities in tumors. The current investor narrative is driven by the company's substantial stock appreciation over the past year, fueled by promising clinical data and strategic partnerships, while the market debates the sustainability of its valuation given the lack of commercial revenue and ongoing R&D expenses.…
TNGX
Tango Therapeutics, Inc.
$27.07
Investment Opinion: Should I buy TNGX Today?
Based on the analysis, TNGX is rated a Buy, driven by the strong buy consensus and the potential for significant upside. The average analyst target of $44.33 implies a 66% upside from the current price of $26.63, and the high target of $69 suggests even greater potential. The company's innovative pipeline, targeting synthetic lethality in cancer, offers a differentiated approach that could lead to substantial value creation if successful.
Sign up to view all
TNGX 12-Month Price Forecast
The AI assessment is bullish on TNGX, driven by the strong analyst consensus and the potential for significant upside. The company's innovative pipeline and healthy balance sheet support a positive outlook, but the lack of revenue and high valuation introduce uncertainty. The stance would be upgraded to high confidence if clinical data shows clear efficacy, or downgraded to neutral if trials disappoint. Key developments to watch include Phase 2 data for TNG462 and any partnership announcements.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tango Therapeutics, Inc.'s 12-month outlook, with a consensus price target around $44.33 and implied upside of +63.8% versus the current price.
Average Target
$44.33
0 analysts
Implied Upside
+63.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$24 - $69
Analyst target range
The target price range spans from $24.00 to $69.00, a wide spread that indicates high uncertainty about the company's clinical and commercial prospects. The high target likely assumes successful clinical trial results and regulatory approvals for its PRMT5 inhibitors, leading to substantial revenue generation. The low target may price in clinical failures or competitive pressures. Recent ratings actions show a mix: Jefferies upgraded from Hold to Buy in June 2026, while Piper Sandler downgraded from Overweight to Neutral in May 2026, suggesting some divergence in analyst views. Overall, the consensus remains strongly bullish, but the wide range highlights the speculative nature of the stock.
Drowning in data?
Find the real signal!
Bulls vs Bears: TNGX Investment Factors
TNGX presents a classic high-risk, high-reward biotech investment. The bull case rests on a promising pipeline, strong analyst support, and a robust balance sheet, while the bear case highlights the lack of revenue, extreme valuation, and significant cash burn. Currently, the bull side has stronger evidence given the strong buy consensus and the potential upside to analyst targets, but the single most important tension is whether the clinical data for TNG462 and TNG456 will justify the premium valuation. If trials succeed, the stock could soar; if they fail, the downside is severe. This binary outcome dominates the investment debate.
Bullish
- Explosive 294.5% 1-Year Stock Rally: TNGX has surged 294.5% over the past year, dramatically outperforming the S&P 500's +15.98% gain. This reflects strong investor conviction in the company's PRMT5 inhibitor pipeline and recent clinical progress, positioning it as a high-momentum biotech leader.
- Strong Buy Consensus with 66% Upside: The 12 analysts covering TNGX rate it a Strong Buy (mean 1.23 on a 1-5 scale), with an average target price of $44.33 versus the current $26.63. This implies a potential upside of approximately 66%, signaling significant expected appreciation.
- High Target Price of $69: The highest analyst target is $69, representing a 159% upside from current levels. This suggests that some analysts see substantial value in the company's pipeline, particularly if TNG462 and TNG456 succeed in clinical trials and achieve regulatory approval.
- Healthy Balance Sheet with Low Debt: TNGX has a debt-to-equity ratio of just 0.097 and a current ratio of 16.3, indicating a strong liquidity position with minimal leverage. This provides financial flexibility to fund ongoing R&D and operations without immediate solvency concerns.
Bearish
- No Recurring Revenue and Heavy Losses: TNGX is pre-revenue, with $0 in revenue in Q1 2026, and posted a net loss of -$45.5 million. The company's reliance on external financing is evident from a negative free cash flow of -$142.5 million TTM, raising sustainability concerns.
- Extreme Valuation with EV/Sales of 61.5x: The EV/Sales ratio of 61.5x is extraordinarily high, even for biotech, implying the market is pricing in massive future revenue that is far from guaranteed. This leaves little room for error and makes the stock vulnerable to sharp de-ratings.
- High Cash Burn Rate: With a net cash burn of -$44.4 million in Q1 2026 alone, TNGX is consuming cash rapidly. At this pace, the company will need to raise capital within the next few years, potentially diluting existing shareholders.
- Wide Analyst Target Range Signals Uncertainty: The analyst target range spans from $24 to $69, a 187% spread, indicating deep disagreement about the company's prospects. This uncertainty is typical of clinical-stage biotechs and can lead to high volatility.
TNGX Technical Analysis
TNGX has experienced a remarkable uptrend over the past year, with a 1-year price change of +294.5%, far outpacing the S&P 500's +15.98%. The stock is currently trading at $26.63, which is 77.4% of its 52-week range (low $5.77, high $34.39), indicating it is well above the lows but has pulled back from its highs. This positioning suggests strong momentum but also potential overextension, as the stock has more than quadrupled from its 52-week low, reflecting high investor enthusiasm.
Beta
1.15
1.15x market volatility
Max Drawdown
-29.2%
Largest decline past year
52-Week Range
$6-$34
Price range past year
Annual Return
+309.5%
Cumulative gain past year
| Period | TNGX Return | S&P 500 |
|---|---|---|
| 1m | -11.7% | +2.4% |
| 3m | +17.6% | +4.6% |
| 6m | +116.4% | +11.7% |
| 1y | +309.5% | +21.4% |
| ytd | +203.1% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TNGX Fundamental Analysis
Tango Therapeutics is a pre-revenue biotech, with quarterly revenue of $0 in Q1 2026, a sharp decline from $53.8 million in Q3 2025 (which included a one-time licensing deal). The company's net loss widened to -$45.5 million in Q1 2026 from -$38.8 million in Q2 2025, reflecting increased R&D spending (R&D expenses of $33.1 million in Q1 2026 vs. $32.2 million in Q2 2025). The lack of recurring revenue and escalating losses indicate a heavy reliance on external financing to fund operations, with a net cash burn of -$44.4 million in Q1 2026.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-142544000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TNGX Overvalued?
Given that TNGX has negative net income (EPS of -$0.32 in Q1 2026), the price-to-sales (P/S) ratio is the primary valuation metric. The trailing P/S ratio is 16.5x, but this is based on minimal revenue, making it less meaningful; the forward P/S is not available. The EV/Sales ratio is 61.5x, which is extremely high, reflecting the market's expectation of substantial future revenue growth from its pipeline. The P/S ratio is not comparable to industry averages due to the lack of revenue, but the EV/Sales multiple is significantly above typical biotech levels, indicating a premium valuation.
PE
-10.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-9.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. TNGX has no recurring revenue, with Q1 2026 revenue of $0, and its net loss widened to -$45.5 million from -$38.8 million in Q2 2025. The company's free cash flow is deeply negative at -$142.5 million TTM, and with a cash burn of -$44.4 million per quarter, it will need to raise capital within the next few years, likely diluting shareholders. The high EV/Sales ratio of 61.5x leaves no margin for error; any setback could trigger a severe de-rating. Additionally, the company's reliance on a single licensing deal for revenue in Q3 2025 highlights the lack of a stable revenue stream.